Rice Hall James & Associates LLC Sells 2,885 Shares of AngioDynamics, Inc. (NASDAQ:ANGO)

Rice Hall James & Associates LLC lowered its holdings in AngioDynamics, Inc. (NASDAQ:ANGO) by 0.9% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 306,635 shares of the medical instruments supplier’s stock after selling 2,885 shares during the period. Rice Hall James & Associates LLC owned approximately 0.77% of AngioDynamics worth $2,386,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Kennedy Capital Management LLC boosted its holdings in AngioDynamics by 425.0% in the 1st quarter. Kennedy Capital Management LLC now owns 190,236 shares of the medical instruments supplier’s stock valued at $1,117,000 after purchasing an additional 154,002 shares during the period. First Eagle Investment Management LLC bought a new stake in AngioDynamics in the 2nd quarter valued at about $1,321,000. Systematic Financial Management LP raised its position in shares of AngioDynamics by 8.4% in the 2nd quarter. Systematic Financial Management LP now owns 2,109,561 shares of the medical instruments supplier’s stock valued at $12,763,000 after buying an additional 162,972 shares in the last quarter. CWM LLC raised its position in shares of AngioDynamics by 981.3% in the 3rd quarter. CWM LLC now owns 9,732 shares of the medical instruments supplier’s stock valued at $76,000 after buying an additional 8,832 shares in the last quarter. Finally, Acadian Asset Management LLC raised its position in shares of AngioDynamics by 11.9% in the 1st quarter. Acadian Asset Management LLC now owns 1,012,186 shares of the medical instruments supplier’s stock valued at $5,940,000 after buying an additional 107,764 shares in the last quarter. Institutional investors own 89.43% of the company’s stock.

AngioDynamics Price Performance

ANGO stock opened at $6.68 on Friday. The company has a 50 day simple moving average of $7.07 and a 200 day simple moving average of $6.69. The stock has a market cap of $271.41 million, a price-to-earnings ratio of -1.10 and a beta of 0.65. AngioDynamics, Inc. has a 1 year low of $5.26 and a 1 year high of $8.25.

AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings data on Thursday, October 3rd. The medical instruments supplier reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.04. The business had revenue of $67.50 million during the quarter, compared to analysts’ expectations of $67.93 million. AngioDynamics had a negative net margin of 83.95% and a negative return on equity of 5.86%. The firm’s quarterly revenue was down 14.2% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.12) EPS. On average, equities research analysts anticipate that AngioDynamics, Inc. will post -0.41 EPS for the current fiscal year.

Insider Buying and Selling at AngioDynamics

In other AngioDynamics news, CEO James C. Clemmer purchased 20,000 shares of the firm’s stock in a transaction on Monday, October 7th. The stock was purchased at an average cost of $6.03 per share, for a total transaction of $120,600.00. Following the transaction, the chief executive officer now owns 681,582 shares in the company, valued at $4,109,939.46. The trade was a 0.00 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In the last ninety days, insiders acquired 22,568 shares of company stock worth $135,847. 5.40% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several brokerages have recently commented on ANGO. HC Wainwright restated a “buy” rating and issued a $14.00 target price on shares of AngioDynamics in a research report on Friday, October 4th. Canaccord Genuity Group dropped their target price on shares of AngioDynamics from $13.00 to $12.00 and set a “buy” rating for the company in a research report on Friday, October 4th.

AngioDynamics Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.